

Sheet 1

RECEIVED
FEB 20 2002
TECH CENTER 1600/2900
09/18/98

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

4821-439

APPLICATION NO.

09/18/98

APPLICANT

FANG *et al.*

FILING DATE

November 16, 2001

GROUP

1614

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|----|-----------------|----------|----------------|-------|----------|----------------------------------|
| <i>10</i> | AA | 5,763,493 | 6/9/98 | Ruff et al. | | | |
| | AB | 5,753,712 | 5/19/98 | Pinsker | | | |
| | AC | 5,731,000 | 3/24/98 | Ruff et al. | | | |
| | AD | 5,541,231 | 7/30/96 | Ruff et al. | | | |
| | AE | 5,512,593 | 4/30/96 | Dante | | | |
| | AF | 5,447,948 | 9/5/95 | Seibyl et al. | | | |
| | AG | 5,427,798 | 6/27/95 | Ludwig et al. | | | |
| | AH | 5,358,970 | 10/25/94 | Ruff et al. | | | |
| | AI | 5,217,987 | 6/8/93 | Berger | | | |
| | AJ | 4,935,439 | 6/19/90 | Kashman et al. | | | |
| | AK | 4,935,429 | 6/19/90 | Dackis et al. | | | |
| | AL | 4,895,845 | 1/23/90 | Seed | | | |
| | AM | 4,868,344 | 9/19/89 | Brown | | | |
| | AN | 4,835,147 | 5/30/89 | Roberts | | | |
| | AO | 4,798,826 | 1/17/89 | Peck | | | |
| | AP | 4,769,027 | 9/6/88 | Baker et al. | | | |
| | AQ | 4,687,660 | 8/18/87 | Baker et al. | | | |
| | AR | 4,656,026 | 4/7/87 | Coffman et al. | | | |
| | AS | 4,571,395 | 2/18/86 | Peck | | | |
| | AT | 4,507,323 | 3/26/85 | Stern | | | |
| | AU | 4,438,138 | 3/20/84 | Stern | | | |
| | AV | 4,435,449 | 3/6/84 | Stern | | | |
| | AW | 4,425,363 | 1/10/84 | Stern | | | |
| | AX | 4,393,078 | 7/12/83 | Peck | | | |
| | AY | 4,356,165 | 10/26/82 | Findlay et al. | | | |
| <i>10</i> | AZ | 4,355,179 | 10/19/82 | Findlay et al. | | | |

| | | | | | | | |
|----|----|-----------|----------|-----------------|--|--|--|
| 18 | BA | 4,347,382 | 8/31/82 | Scharver | | | |
| | BB | 4,347,257 | 8/31/82 | Stern | | | |
| | BC | 4,347,178 | 8/31/82 | Findlay et al. | | | |
| | BD | 4,347,177 | 8/31/82 | Phillips | | | |
| | BE | 4,347,176 | 8/31/82 | Mehta | | | |
| | BF | 4,008,719 | 2/22/77 | Theeuwes et al. | | | |
| | BG | 3,960,927 | 6/1/76 | Metcalf et al. | | | |
| | BH | 3,916,899 | 11/4/75 | Theeuwes et al. | | | |
| | BI | 3,885,046 | 5/20/75 | Mehta | | | |
| | BJ | 3,845,770 | 11/5/74 | Theeuwes et al. | | | |
| | BK | 3,819,706 | 6/25/74 | Mehta | | | |
| | BL | 3,630,200 | 12/28/71 | Higuchi | | | |
| | BM | 3,622,675 | 11/23/71 | Koppe et al. | | | |
| | BN | 3,598,123 | 8/10/71 | Zaffaroni | | | |
| | BO | 3,536,809 | 10/27/70 | Applezweig | | | |
| 19 | BP | RE 33,994 | 7/14/92 | Baker et al. | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|----|----|-----------------|----------|---------|-------|----------|-------------|----|
| | | | | | | | YES | NO |
| 18 | BQ | WO 95/22324 | 8/24/95 | PCT | | | | |
| | BR | WO 94/20100 | 9/15/94 | PCT | | | | |
| | BS | WO 94/04138 | 3/3/94 | PCT | | | | |
| | BT | WO 93/21917 | 11/11/93 | PCT | | | | |
| | BU | WO 91/11184 | 8/8/91 | PCT | | | | |
| | BV | WO 92/19226 | 11/12/92 | PCT | | | | |
| | BW | WO 95/03791 | 2/09/95 | PCT | | | | |
| | BX | WO 96/39133 | 12/12/96 | PCT | | | | |
| | BY | WO 97/29735 | 8/21/97 | PCT | | | | |
| | BZ | WO 98/50044 | 11/12/98 | PCT | | | | |
| | CA | WO 99/37305 | 7/29/99 | PCT | | | | |
| | CB | 0 467 488 | 1/22/92 | EPO | | | | |
| | CC | 0 171 227 | 2/12/86 | EPO | | | | |
| | CD | 0 118 036 | 9/12/84 | EPO | | | | |
| 19 | CE | 977778 | 11/11/75 | CA | | | | |

| | | | | | | | | | |
|---|---|----------|----|--|--|--|--|--|--|
| CF | 977777 | 11/11/75 | CA | | | | | | |
| CG | 63-91352 | 4/22/88 | JP | | | | | | |
| OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | |
| CH | Ascher, J.A. et al., 1995, "Bupropion: a review of its mechanism of antidepressant activity", J. Clin. Psych. 56:395-401. | | | | | | | | |
| CI | Bannon et al., 1998, "Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors", Science 279:77-81. | | | | | | | | |
| CJ | Bischoff et al., 1984, "Affinity changes of rat striatal dopamine receptor in vivo after acute bupropion treatment", Eur. J. Pharmacol. 104:173-176. | | | | | | | | |
| CK | Blondel-Hill et al., 1993, "Treatment of the chronic fatigue syndrome", Drugs 46(4):639-651. | | | | | | | | |
| CL | Borowski, T.B. et al., 1993, "Amphetamine and antidepressant drug effects on GABA- and NMDA-related seizures", Brain Res. Bull. 30:607-610. | | | | | | | | |
| CM | Calabrese, J.R. et al., 1991, "Treatment of depression", Primary Care 18(2):421-433. | | | | | | | | |
| CN | Castaldi, G. et al., 1987, "Tartaric acid, an efficient chiral auxiliary: new asymmetric synthesis of 2-alkyl-2-arylacetic acids", J. Org. Chem. 52:3018. | | | | | | | | |
| CO | Castello, R.A. and Mattocks, A.M., J. Pharm. Sci. 51(2):106-108 (1962). | | | | | | | | |
| CP | Charney, D.S. et al., 1983, "Monoamine receptor sensitivity and depression: clinical studies of antidepressant effects on serotonin and noradrenergic function," Psychopharmacol. Bull. 19(3):490. | | | | | | | | |
| CQ | Clay et al., 1988, "Clinical and neuropsychological effects of the novel antidepressant bupropion", Psychopharmacol. Bull. 24(1):143-148. | | | | | | | | |
| CR | Conners, K.C. et al., 1996, "Bupropion hydrochloride in attention deficit disorder with hyperactivity", J. Am. Acad. Child Adolesc. Psychiatr. 34(10):1314-1321. | | | | | | | | |
| CS | Cooke C.E., 1997, "Therapeutic advances in the treatment of cigarette addiction", J. Pharmacy Practice 10(5):329-337. | | | | | | | | |
| CT | Cooper, B.R. et al., 1994, "Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin®) are mediated by a noradrenergic mechanism", Neuropsychopharmacology 11(2):133-141. | | | | | | | | |
| CU | Cooper, T.B. et al., Analytical psychopharmacology: NY State Psychiatric Institute pp. 1-3. | | | | | | | | |
| CV | Coutts, R.T. & Baker, G.B., 1989, "Implications of chirality and geometric isomerisms in some psychoactive drugs and their metabolites", Chirality 1:99-120. | | | | | | | | |
| CW | Crenshaw et al., 1987, "Pharmacological modification of psychosexual dysfunction", J. Sex. Marital Ther. 13(4):239-252. | | | | | | | | |
| CX | Cusack, B. et al., 1994, "Binding of antidepressants to human brain receptors: focus on newer generation compounds", Psychopharmacol. 114:559-565. | | | | | | | | |
| CY | Davidson et al., 1994, "Bupropion in chronic low back pain", J. Clin. Psychiatry 55(8):362. | | | | | | | | |

| | | |
|----|----|---|
| 10 | CZ | Dilsaver, S.C. et al., 1992, "The efficacy of bupropion in winter depression: results of an open trial", J. Clin. Psychiatry 53(7):252-255. |
| | DA | Eliel, E.L., 1962, Stereochemistry of Carbon Compounds, McGraw-Hill, NY. |
| | DB | Ferris, R.M. et al., 1983, "Studies of bupropion's mechanism of antidepressant activity", J. Clin. Psychiatry 44(5):74-78. |
| | DC | Ferris & Beaman, 1983, "Bupropion: a new antidepressant drug, the mechanism of action of which is not associated with down-regulation of postsynaptic β -adrenergic, serotonergic (5-HT ₂), α_2 -adrenergic, imipramine and dopaminergic receptors in brain", Neuropharmacol. 22(1):1257-1267. |
| | DD | Ferry, L.H. et al., 1992, "Enhancement of smoking cessation using the anti-depressant bupropion hydrochloride" (abstract) Circulation 86:671. |
| | DE | Ferry, L.H. et al., 1994, "Efficacy of bupropion for smoking cessation in non-depressed smokers," J. Addict. Dis. 13:A9. |
| | DF | Fisher, R.S., 1989, "Animal models of the epilepsies", Brain Res. Reviews 14:245-278. |
| | DG | Foot et al., 1984, "Proconvulsant effect of morphine on seizures induced by pentylenetetrazol in the rat", 105:179-184. |
| | DH | Garland et al., 1998, "Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats", J. Psychopharmacology 12(4):385-395. |
| | DI | Goetz et al., 1984, "Bupropion in Parkinson's Disease," 34:1092-4. |
| 11 | DJ | Goodnick, P.J., 1994, "Pharmacokinetic optimisation of therapy with newer antidepressants", Clin. Pharmacokinet. 27(4):307-330. |
| | DK | Goodnick, P.J. & Sandoval, R., 1993, "Psychotropic treatment of depression: results of an open trial", J. Clin. Psych. 54(1):13-20. |
| | DL | Green, A.R. & Murray, T.K., 1989, "A simple intravenous infusion method in rodents for determining the potency of anticonvulsants acting through GABAergic mechanisms", J. Pharm. Pharmacol. 41:879-880. |
| | DM | Grimes et al., 1996, "Spontaneous orgasm with the combined use of bupropion and sertraline", Soc. Biol. Psych. 40:1184-1185. |
| | DN | Handbook of Pharmaceutical Excipients, 2nd ed., Wade and Willer eds., pp. 257-259 (1994). |
| | DO | Hsyu, P.H. et al., 1997, "Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers", J. Clin. Pharmacol. 37(8):737-743. |
| | DP | Hsyu, P.H. et al., 10 November 1997 Chemical Abstracts 127(19): Abstract no. 257089; Columbus, Ohio. |
| | DQ | Janowsky, A., et al., J. Neurochem. 46:1272-1276 (1986). |
| | DR | Kelley, J.L. et al., 1996, "(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol: a novel antidepressant agent and selective inhibitor of norepinephrine uptake", J. Med. Chem. 39:347-349. |

| | | |
|----|----|--|
| 10 | DS | Ketter, T.A. et al., 1995, "Carbamazepine but not valproate induces bupropion metabolism", J. Clin. Psychopharmacol. 15(5):327-333. |
| | DT | Laizure, S.C. et al., 1985, "Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose", Clin. Pharmacol. Ther. 38:586-589. |
| | DU | Lief, H.I., 1996, "Bupropion treatment of depression to assist smoking cessation", Am. J. Psychiatry 153(3):442. |
| | DV | Little, K.Y. et al., 1993, "[¹²⁵ I]RTI-55 binding to cocaine-sensitive dopaminergic and serotonergic uptake sites in the human brain", J. Neurochem. 61:1996-2006. |
| | DW | Martin, P. et al., 1990, "Antidepressant Profile of Bupropion and Three Metabolites in Mice," Pharmacopsychiatry 23:187-194. |
| | DX | McNamee et al., 1986, "Stimulation of substrate oxidation in rat hepatic mitochondria following pretreatment with appetite modifying drugs", J. Pharm. Pharmacol. 37:147. |
| | DY | Merskey, H., 1965, "The effect of chronic pain upon the response to noxious stimuli by psychiatric patients," J. Psychosom. Res. 8:405-419. |
| | DZ | Michell, G.F. et al., 1989, "Effect of bupropion on chocolate craving", Am. J. Psychiatry 146(1):119-120. |
| | EA | Michell, G.F. et al., 1989, "Dr. Mitchell and associates reply", Am. J. Psychiatry 146(8):1089. |
| | EB | Moisset, B., et al., Brain Res. 92:157-164 (1975). |
| | EC | Moret, C. & Brile, M., 1988, "Sensitizing of the response of 5-HT autoreceptors to drugs modifying synaptic availability of 5-HT", 27(1):43-49. |
| | ED | Musso et al., 1993, "Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion", Chirality 5:495-500. |
| | EE | Musso et al., 1997, "Synthesis and Evaluation of the Anticonvulsant Activity of a Series of 2-Amino-Phenyl-1-Propanols Derived from the Metabolites of the Antidepressant Bupropion," Bioorganic & Medical Chemistry Letters, Vol. 7 No 1, pp 1-6, 1997. |
| | EF | Neurology, Official Journal of American Academy of Neurology, August 1984, volume 34, Number 8 |
| | EG | Nomikos et al., 1992, "Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum", Neuropsychopharmacology 7(1):7-14. |
| | EH | Nutt, D.J. et al., 1981, "Studies on the postictal rise in seizure threshold, " Eur. J. Pharmacol. 71:287-295. |
| | EI | Nutt, D.J. Et al., 1980, "On the measurement in rats of the convulsant effect of drugs and the changes which follow electroconvulsive shock," Neuropharmacology 19:1017-1023. |
| | EJ | Olsen et al., 1985, "Benzodiazepine/γ-aminobutyric acid receptor deficit in the midbrain of the seizure-susceptible gerbil", PNAS USA 82:6701-6705. |
| 11 | EK | Pearlstein et al., 1997, "Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder", J. Clin. Psychopharmacol. 17(4):261-266. |

| | | |
|-----|----|--|
| 109 | EL | Perovic, S. and Mueller, W.E.G., Brain Res. 92:157-164 (1995) |
| | EM | Physician's Desk Reference®, (1998) pages 1120-1127. |
| | EN | Popli, A.P. et al., 1994, "Antidepressant-associated seizures", J. Clin. Psych. 55(6):267. |
| | EO | Popli, A. et al., 1995, "Bupropion and anticonvulsant drug interactions", Annals of Clin. Psychiatr. 7(2):99-101. |
| | EP | Posner, J. et al., 1985, "The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses", Eur. J. Clin. Pharmacol. 29:97-103. |
| | EQ | Potter, W.Z. & Manji, H.K., 1990, "Antidepressants, metabolites, and apparent drug resistance", Clin. Neuropharmacol. 13(1):S45-S53. |
| | ER | Remingtons: The Practice of the Science and Pharmacy, 19th ed., Gennaro, ed., p. 1625 (1995). |
| | ES | Rose, J.E., 1996, "Nicotine addiction and treatment", Annu. Rev. Med. 47:493-507. |
| | ET | Rosenstein, D.L. et al., 1993, "Seizures associated with antidepressants: a review", J. Clin. Psychiatry 54(8):289-299. |
| | EU | Rudorfer, M.V. et al., 1994, "Comparative tolerability profiles of the newer versus older antidepressants", Drug Safety 10(1):18-46. |
| | EV | Schroeder, D.H., 1983, "Metabolism and kinetics of bupropion", J. Clin. Psychiatr. 44(5):79-81. |
| | EW | Schroedger, D.H. et al., 1979, "The isolation and identification of some basic urinary metabolites of bupropion - HCL in man", The Pharmacologist 21(3):191. |
| | EX | SCRIP Bupropion Sustained Release (SR) for Smoking Cessation, 12/18/96. |
| | EY | SCRIP Itraconazole for 'pulse' dosing of onychomycosis, 12/18/96. |
| | EZ | Scrip's New Product Review, No. 50 Bupropion, PJB Publications: United Kingdom, August, 1990. |
| | FA | Stathis, M. et al., 1995, "Rate of binding of various inhibitors at the dopamine transporter in vivo", Psychopharmacol. 119:376-384. |
| | FB | Storrow, A.B., 1994, "Bupropion overdose and seizure", Am. J. Emerg. Med. 12:183-184. |
| | FC | Suckow, R.F. et al., 1986, "Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs", Drug Metab. Disposit. 14(6):692-697. |
| | FD | Suckow, R.F. et al., 1997, "Enantiomeric determination of the phenylmorpholinol metabolite of bupropion in human plasma using coupled achiral-chiral liquid chromatography", Biomedical Chromatog. 11:174-179. |
| | FE | Sulser, F., 1983, "Molecular mechanisms in antidepressant action," Psychopharmacol. Bull. 19(3):300. |
| | FF | Sweet, R.A. et al., 1995, "Pharmacokinetics of single- and multiple- dose bupropion in elderly patients with depression", J. Clin. Pharmacol. 35:876-884. |
| 110 | FG | Testa B. and Trager, W.F., 1990, "Racemates Versus Enantiomers in Drug Development: Dogmatism or Pragmatism?" Chirality 2:129-133. |

| | | |
|--|----|--|
| | FH | Vassout, A. et al. (1993) "Regulation of dopamine receptors by bupropion: comparison with antidepressants and CNS stimulants", J. Receptor Res. 13(1-4):341-354. |
| | FI | Ward, N.G. (1990) <u>The Management of Pain</u> , Second Edition, Vol. 1, Chapter 18 (eds.) Bonica, J.J. pp. 310-319. |
| | FJ | Ward, R. et al. (1971) "Asymmetric audiogenic seizures in mice: a possible analogue of focal epilepsy", Brain Res. 31:207-210. |
| | FK | Welch, R.M. et al. (1987) "Pharmacological significance of the species differences in bupropion metabolism", Neurobiologia 17(3):287-298. |
| | FL | Willen, S.H. (1972) <u>Tables of Resolving Agents and Optical Resolutions</u> , Univ. of Notre Dame Press, Notre Dame, IN. |
| | FM | Wright et al. (1985) "Bupropion in the long-term treatment of cyclic mood disorders: mood stabilizing effects", J. Clin. Psych. 46(1):22-25. |
| | FN | Zarrindast et al. (1988) "Anorectic and behavioral effects of bupropion", Gen. Pharmacology 19(2):201-204. |
| EXAMINER | | DATE CONSIDERED 9/20/03 |
| <p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> | | |

| | | | | | | | |
|---|--|--|------|--------------------------|-------|-----------------|----------------------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | | | | ATTY. DOCKET NO. | | APPLICATION NO. | |
| | | | | 4821-439 | | 09/987,931 | |
| | | | | APPLICANT FANG et al. | | | |
| | | | | FILING DATE | | GROUP | |
| | | | | November 16, 2001 | | 1614 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION |
| | | | | | | | YES NO |
| OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
| FO | | Adeoye et al. "Bupropion Plasma Concentration and Antidepressant response in elderly patients: A Prospective, Randomized, Double-Blind Study" Int. J. Geriatr. Psychopharmacol (2000) pg. 132, col. 2, paragraph 3 | | | | | |
| FP | | Pollock B. G. et al. "Bupropion Plasma Levels and CYP2D6 Phenotype" Ther. Drug Monit. (1996), 18 (5), pp. 581-585 | | | | | |
| FQ | | Perumal A.S. et al. "Down-Regulation of Beta-Receptors by Bupropion and its Major Metabolite in Mouse Brain" Neuropharmacology (1986), 25 (12), 1323-6 | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |
| | | | | 9/20/03 | | | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |

RECEIVED

JUN 26 2002

TECH CENTER 1600/2900